title: The rationale behind a vaccine based on multiple HIV antigens.
abstract: The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on multiple HIV-1 DNA immunogens together with adjuvant recombinant granulocyte-macrophage stimulating factor. This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials.
authors.affiliation: Swedish Institute for Infectious Disease Control, Solna, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Rollman
authors.forename: A
authors.initials: A
authors.lastname: Bråve
authors.forename: A
authors.initials: A
authors.lastname: Boberg
authors.forename: L
authors.initials: L
authors.lastname: Gudmundsdotter
authors.forename: G
authors.initials: G
authors.lastname: Engström
authors.forename: M
authors.initials: M
authors.lastname: Isaguliants
authors.forename: K
authors.initials: K
authors.lastname: Ljungberg
authors.forename: B
authors.initials: B
authors.lastname: Lundgren
authors.forename: P
authors.initials: P
authors.lastname: Blomberg
authors.forename: J
authors.initials: J
authors.lastname: Hinkula
authors.forename: B
authors.initials: B
authors.lastname: Hejdeman
authors.forename: E
authors.initials: E
authors.lastname: Sandström
authors.forename: M
authors.initials: M
authors.lastname: Liu
authors.forename: B
authors.initials: B
authors.lastname: Wahren
mesh_terms: D016915:AIDS Vaccines / Q000235:genetics* / Q000276:immunology*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D015683:Gene Products, gag / Q000235:genetics / Q000276:immunology; D015693:Gene Products, nef / Q000235:genetics / Q000276:immunology; D015694:Gene Products, rev / Q000235:genetics / Q000276:immunology; D015696:Gene Products, tat / Q000235:genetics / Q000276:immunology; D015488:HIV Antigens / Q000235:genetics* / Q000276:immunology*; D019302:HIV Envelope Protein gp160 / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D054303:HIV Reverse Transcriptase / Q000235:genetics / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D009052:Leukemia Virus, Murine; D051379:Mice; D008810:Mice, Inbred C57BL; D017778:Vaccines, Combined / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D054311:nef Gene Products, Human Immunodeficiency Virus; D054321:rev Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus
chemical_list: D016915:AIDS Vaccines; D015683:Gene Products, gag; D015693:Gene Products, nef; D015694:Gene Products, rev; D015696:Gene Products, tat; D015488:HIV Antigens; D019302:HIV Envelope Protein gp160; D017778:Vaccines, Combined; D019444:Vaccines, DNA; D054311:nef Gene Products, Human Immunodeficiency Virus; D054321:rev Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus; D054303:HIV Reverse Transcriptase